Trial · NCT02363322
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
NCT02363322, Phase 1, Phase 2, Completed, National Institute of Allergy and Infectious Diseases (NIAID); results first posted 2019-05-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection. Trials, record NCT02363322. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02363322
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
- NCT number
- NCT02363322
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 72 participants, actual
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Conditions
- Ebola Virus Infection
- Interventions
- B/Current Standard of Care Plus ZMapp, A/Current Standard of Care Alone
- First posted
- 2015-02-16
- Last updated
- 2019-06-05
- Results first posted
- 2019-05-14
- Limitations and caveats
- Due to the severity of the underlying illness (Ebola infection) only infusion-related adverse events were captured.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality | 28 days | Death at Day 28 |
| Secondary | Number of Participants With ZMapp Infusion-related Adverse Events | 10 Days | Adverse events related to ZMapp infusions |
| Secondary | Plasma Viral Load | 28 days | Time to viral clearance |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mortality | 28 days | Seven of the eight deaths recorded in ZMapp recipients occurred before day 4, before the second of three planned infusions of ZMapp. The exception was one patient who received a second infusion on day 4 and died later that day. In the group that received the current standard of care alone, all 13 deaths occurred during the first 8 days of follow-up | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With ZMapp Infusion-related Adverse Events | 10 Days | Arm A Received the Current Standard of Care Alone and not the ZMapp infusion | participants | NUMBER |
| SECONDARY | Plasma Viral Load | 28 days | days | MEDIAN |
Source ClinicalTrials.gov
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mortality | A/Current Standard of Care Alone | 13 | Participants | ||
| Mortality | B/Current Standard of Care Plus ZMapp | 8 | Participants | ||
| Number of Participants With ZMapp Infusion-related Adverse Events | B/Current Standard of Care Plus ZMapp | Hypotension | 7 | participants | |
| Number of Participants With ZMapp Infusion-related Adverse Events | B/Current Standard of Care Plus ZMapp | Elevation in fever | 8 | participants | |
| Number of Participants With ZMapp Infusion-related Adverse Events | B/Current Standard of Care Plus ZMapp | Tachycardia | 4 | participants | |
| Number of Participants With ZMapp Infusion-related Adverse Events | B/Current Standard of Care Plus ZMapp | Tachypnea | 3 | participants | |
| Number of Participants With ZMapp Infusion-related Adverse Events | B/Current Standard of Care Plus ZMapp | Hypertension | 3 | participants | |
| Number of Participants With ZMapp Infusion-related Adverse Events | B/Current Standard of Care Plus ZMapp | Confusion | 2 | participants | |
| Number of Participants With ZMapp Infusion-related Adverse Events | B/Current Standard of Care Plus ZMapp | Seizure | 1 | participants | |
| Number of Participants With ZMapp Infusion-related Adverse Events | B/Current Standard of Care Plus ZMapp | Difficulty Breathing | 1 | participants |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | A/Current Standard of Care Alone | 36 | |
| Overall Study | STARTED | B/Current Standard of Care Plus ZMapp | 36 | |
| Overall Study | COMPLETED | A/Current Standard of Care Alone | 35 | |
| Overall Study | COMPLETED | B/Current Standard of Care Plus ZMapp | 36 | |
| Overall Study | NOT COMPLETED | A/Current Standard of Care Alone | 1 | |
| Overall Study | NOT COMPLETED | B/Current Standard of Care Plus ZMapp | 0 |
Source ClinicalTrials.gov
Adverse events46
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypotension | Vascular disorders | A/Current Standard of Care Alone | 35 | ||
| other | Hypotension | Vascular disorders | B/Current Standard of Care Plus ZMapp | 7 | 36 | 7 |
| other | Elevation in Fever | Infections and infestations | A/Current Standard of Care Alone | 35 | ||
| other | Elevation in Fever | Infections and infestations | B/Current Standard of Care Plus ZMapp | 8 | 36 | 8 |
| other | Tachycardia | Vascular disorders | A/Current Standard of Care Alone | 35 | ||
| other | Tachycardia | Vascular disorders | B/Current Standard of Care Plus ZMapp | 4 | 36 | 4 |
| other | Tachypnea | Respiratory, thoracic and mediastinal disorders | A/Current Standard of Care Alone | 35 | ||
| other | Tachypnea | Respiratory, thoracic and mediastinal disorders | B/Current Standard of Care Plus ZMapp | 3 | 36 | 3 |
| other | Hypertension | Vascular disorders | A/Current Standard of Care Alone | 35 | ||
| other | Hypertension | Vascular disorders | B/Current Standard of Care Plus ZMapp | 3 | 36 | 3 |
1 to 10 of 46Source ClinicalTrials.gov
See all 46 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | A/Current Standard of Care Alone | 13 | 35 |
| Total, all-cause mortality | B/Current Standard of Care Plus ZMapp | 8 | 36 |
| Total, other adverse events | A/Current Standard of Care Alone | 0 | 35 |
| Total, other adverse events | B/Current Standard of Care Plus ZMapp | 32 | 36 |
| Total, serious adverse events | A/Current Standard of Care Alone | 13 | 35 |
| Total, serious adverse events | B/Current Standard of Care Plus ZMapp | 11 | 36 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: Mortality | Trial comparisons |
| B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: deaths from any cause | Trial comparisons |
| B/Current Standard of Care Plus ZMapp vs A/Current Standard of Care Alone: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02363322
GET https://conductscience.org/api/trials/v1/NCT02363322/events?page=2